{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T19:56:58Z","timestamp":1793390218719,"version":"4.5.0"},"reference-count":39,"publisher":"American Medical Association (AMA)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Obesity, a chronic disease with escalating global prevalence, poses considerable health risks. Glucagon-like peptide 1 receptor agonists (GLP-1RAs), including liraglutide, semaglutide, and tirzepatide, have demonstrated efficacy for weight loss in clinical trials. The paradigm shift in the approach to obesity management drugs (OMDs) may offer an opportunity to examine online search activity and prescription trends.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To investigate prescription patterns and online search trends for OMD and correlating usage dynamics with public engagement regarding these medications.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This repeated cross-sectional study analyzed online searches and corresponding data for dispensed prescriptions derived from the IQVIA National Prescription Audit, a comprehensive audit capturing\u2009approximately\u200990% of US retail prescription dispensing that is then projected to population-level data. Data from online searches and on prescriptions from the National Prescription Audit for US Food and Drug Administration\u2013approved OMDs were collected from July 1, 2017, through February 29, 2024. This population-level analysis included all eligible individuals using either the Google search engine or receiving prescriptions.<\/jats:p>\n <\/jats:sec>\n \n Exposures<\/jats:title>\n US monthly query fractions as online searches per 10 million total searches and monthly prescriptions dispensed for OMDs.<\/jats:p>\n <\/jats:sec>\n \n Main Outcome and Measures<\/jats:title>\n Trends in OMD prescriptions and online searches were visually analyzed, and quantitative correlations were calculated using Spearman rank correlation.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n During the study period, 69 213 936 prescriptions for OMDs were dispensed in the US, with an overall increase of 0.76 to 0.80 million from July 2017 to June 2018 and 1.29 to 1.51 million from March 2023 to February 2024 and a mean (SD) annual growth rate of 5.3% (9.4%). Total monthly OMD prescriptions reached 1.5 million in February 2024, accounting for 0.41% of all prescriptions that month. Phentermine, semaglutide (Wegovy; Novo Nordisk), liraglutide (Saxenda; Novo Nordisk), and tirzepatide (Zepbound; Eli Lilly) were most prescribed. By February 2024, phentermine had approximately 0.74 million monthly prescriptions, Wegovy had 0.42 million, and Zepbound had 0.25 million. Most prescriptions were issued by advanced practice practitioners (APP) and primary care physicians (PCPs) and internists. The APPs\u2019 share increased from 25.3% in July 2017 to 40.6% in February 2024, while PCPs\u2019 and internists\u2019 share decreased from 57.9% to 48.1%. Wegovy\u2019s share of total OMDs increased to 27.7% and 28.3% and Zepbound\u2019s share to 16.1% and 16.5% (both February 2024) among APPs and PCPs and internists, respectively. Phentermine\u2019s dropped from 86.3% and 85.1% (July 2017) to 50.8% and 49.7% (February 2024), respectively. Online searches per 10 million reflected prescription trends, with Wegovy at 636.3, Zepbound at 468.9, and phentermine at 301.8 (all February 2024). The strongest correlations between prescriptions and search volumes were observed for semaglutide (Wegovy;\n r<\/jats:italic>\n \u2009=\u20090.97) and tirzepatide (Zepbound;\n r<\/jats:italic>\n \u2009=\u20090.90).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n This repeated cross-sectional study shows the dynamic growth and evolving share of new obesity medications since 2017 and a significant shift toward semaglutide and tirzepatide prescribing. The joint surge in prescriptions and online searches and their close correlation highlight the real-time associations between public awareness and prescription trends.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2024.57232","type":"journal-article","created":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T12:40:18Z","timestamp":1738154418000},"page":"e2457232","source":"Crossref","is-referenced-by-count":83,"title":["Longitudinal Analysis of Obesity Drug Use and Public Awareness"],"prefix":"10.1001","volume":"8","author":[{"given":"Philipp","family":"Berning","sequence":"first","affiliation":[{"name":"Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rishav","family":"Adhikari","sequence":"additional","affiliation":[{"name":"Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian E.","family":"Schroer","sequence":"additional","affiliation":[{"name":"Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yara A.","family":"Jelwan","sequence":"additional","affiliation":[{"name":"Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander C.","family":"Razavi","sequence":"additional","affiliation":[{"name":"Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Blaha","sequence":"additional","affiliation":[{"name":"Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Dzaye","sequence":"additional","affiliation":[{"name":"Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, Maryland"},{"name":"Division of Vascular and Interventional Radiology, Department of Radiology, University of Texas Southwestern Medical Center, Dallas, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2025,1,29]]},"reference":[{"issue":"1","key":"zoi241598r2","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa1614362","article-title":"Health effects of overweight and obesity in 195 countries over 25 years.","volume":"377","author":"Afshin","year":"2017","journal-title":"N Engl J Med"},{"issue":"360","key":"zoi241598r3","first-page":"1","article-title":"Prevalence of obesity and severe obesity among adults: United States, 2017-2018.","author":"Hales","year":"2020","journal-title":"NCHS Data Brief"},{"issue":"10046","key":"zoi241598r4","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/S0140-6736(16)30175-1","article-title":"Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents.","volume":"388","author":"Di Angelantonio","year":"2016","journal-title":"Lancet"},{"issue":"2","key":"zoi241598r5","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1056\/NEJMoa1212914","article-title":"Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes.","volume":"369","author":"Wing","year":"2013","journal-title":"N Engl J Med"},{"issue":"8","key":"zoi241598r6","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.27358","article-title":"Probability of 5% or greater weight loss or BMI reduction to healthy weight among adults with overweight or obesity.","volume":"6","author":"Kompaniyets","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"3","key":"zoi241598r7","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1056\/NEJMra1514009","article-title":"Mechanisms, pathophysiology, and management of obesity.","volume":"376","author":"Heymsfield","year":"2017","journal-title":"N Engl J Med"},{"key":"zoi241598r8","doi-asserted-by":"publisher","first-page":"g2646","DOI":"10.1136\/bmj.g2646","article-title":"Long term maintenance of weight loss with non-surgical interventions in obese adults: systematic review and meta-analyses of randomised controlled trials.","volume":"348","author":"Dombrowski","year":"2014","journal-title":"BMJ"},{"key":"zoi241598r9","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.101882","article-title":"Pharmacotherapy of obesity: an update on the available medications and drugs under investigation.","volume":"58","author":"Chakhtoura","year":"2023","journal-title":"EClinicalMedicine"},{"key":"zoi241598r10","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.101213","article-title":"Association of glucagon-like peptide 1 analogs and agonists administered for obesity with weight loss and adverse events: a systematic review and network meta-analysis.","volume":"42","author":"Vosoughi","year":"2021","journal-title":"EClinicalMedicine"},{"issue":"22","key":"zoi241598r11","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1001\/jama.2023.24539","article-title":"FDA green-lights tirzepatide, marketed as Zepbound, for chronic weight management.","volume":"330","author":"Abbasi","year":"2023","journal-title":"JAMA"},{"issue":"3","key":"zoi241598r12","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity.","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"issue":"10278","key":"zoi241598r13","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","article-title":"Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial.","volume":"397","author":"Davies","year":"2021","journal-title":"Lancet"},{"issue":"11","key":"zoi241598r14","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity.","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"issue":"4","key":"zoi241598r15","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1111\/dom.14940","article-title":"Tirzepatide versus semaglutide for weight loss in patients with type 2 diabetes mellitus: a value for money analysis.","volume":"25","author":"Azuri","year":"2023","journal-title":"Diabetes Obes Metab"},{"issue":"14","key":"zoi241598r16","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1001\/jama.2021.1831","article-title":"Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial.","volume":"325","author":"Wadden","year":"2021","journal-title":"JAMA"},{"issue":"10160","key":"zoi241598r17","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1016\/S0140-6736(18)32260-8","article-title":"Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.","volume":"392","author":"Frias","year":"2018","journal-title":"Lancet"},{"issue":"19","key":"zoi241598r18","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1001\/jama.2023.2438","article-title":"As Ozempic\u2019s popularity soars, here\u2019s what to know about semaglutide and weight loss.","volume":"329","author":"Suran","year":"2023","journal-title":"JAMA"},{"issue":"3","key":"zoi241598r19","doi-asserted-by":"publisher","first-page":"467","DOI":"10.2337\/cd23-0023","article-title":"Special report: potential strategies for addressing GLP-1 and dual GLP-1\/GIP receptor agonist shortages.","volume":"41","author":"Whitley","year":"2023","journal-title":"Clin Diabetes"},{"issue":"4","key":"zoi241598r20","doi-asserted-by":"publisher","first-page":"985","DOI":"10.2337\/dc13-2097","article-title":"Ambulatory treatment of type 2 diabetes in the U.S., 1997-2012.","volume":"37","author":"Turner","year":"2014","journal-title":"Diabetes Care"},{"issue":"9","key":"zoi241598r21","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.023811","article-title":"National trends in use of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists by cardiologists and other specialties, 2015 to 2020.","volume":"11","author":"Adhikari","year":"2022","journal-title":"J Am Heart Assoc"},{"issue":"3","key":"zoi241598r22","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.amepre.2015.02.020","article-title":"Trends in opioid analgesic-prescribing rates by specialty, U.S., 2007-2012.","volume":"49","author":"Levy","year":"2015","journal-title":"Am J Prev Med"},{"issue":"12","key":"zoi241598r23","doi-asserted-by":"publisher","DOI":"10.2196\/41527","article-title":"Characterizing help-seeking searches for substance use treatment from Google trends and assessing their use for infoveillance: longitudinal descriptive and validation statistical analysis.","volume":"24","author":"Patton","year":"2022","journal-title":"J Med Internet Res"},{"issue":"2","key":"zoi241598r24","doi-asserted-by":"publisher","DOI":"10.2196\/19369","article-title":"Collateral crises of gun preparation and the COVID-19 pandemic infodemiology study.","volume":"6","author":"Caputi","year":"2020","journal-title":"JMIR Public Health Surveill"},{"key":"zoi241598r25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.884211","article-title":"Association of online search trends with vaccination in the United States: June 2020 through May 2021.","volume":"13","author":"Berning","year":"2022","journal-title":"Front Immunol"},{"issue":"19","key":"zoi241598r26","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes.","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"2","key":"zoi241598r27","doi-asserted-by":"publisher","first-page":"297","DOI":"10.3945\/ajcn.111.024927","article-title":"Two-year sustained weight loss and metabolic benefits with controlled-release phentermine\/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study.","volume":"95","author":"Garvey","year":"2012","journal-title":"Am J Clin Nutr"},{"issue":"1","key":"zoi241598r28","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"A randomized, controlled trial of 3.0 mg of liraglutide in weight management.","volume":"373","author":"Pi-Sunyer","year":"2015","journal-title":"N Engl J Med"},{"issue":"10295","key":"zoi241598r29","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S0140-6736(21)01324-6","article-title":"Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.","volume":"398","author":"Rosenstock","year":"2021","journal-title":"Lancet"},{"issue":"9774","key":"zoi241598r30","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/S0140-6736(11)60205-5","article-title":"Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial.","volume":"377","author":"Gadde","year":"2011","journal-title":"Lancet"},{"issue":"2","key":"zoi241598r31","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/oby.2011.330","article-title":"Controlled-release phentermine\/topiramate in severely obese adults: a randomized controlled trial (EQUIP).","volume":"20","author":"Allison","year":"2012","journal-title":"Obesity (Silver Spring)"},{"key":"zoi241598r32","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.936651","article-title":"Online searches for SGLT-2 inhibitors and GLP-1 receptor agonists correlate with prescription rates in the United States: an infodemiological study.","volume":"9","author":"Dzaye","year":"2022","journal-title":"Front Cardiovasc Med"},{"issue":"7","key":"zoi241598r33","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.21305","article-title":"Glucagon-like peptide 1 receptor agonists and 13 obesity-associated cancers in patients with type 2 diabetes.","volume":"7","author":"Wang","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"2","key":"zoi241598r34","article-title":"High demand keeps some diabetes medications in short supply: pharmaceutical companies are experiencing supply chain disruptions and shortages because of the popularity of diabetes drugs used for weight loss.","volume":"167","author":"Blank","year":"2023","journal-title":"Drug Top"},{"issue":"10","key":"zoi241598r35","article-title":"Losing weight, gaining value.","volume":"47","author":"Thomas","year":"2023","journal-title":"Pharm Technol"},{"issue":"10402","key":"zoi241598r36","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/S0140-6736(23)01200-X","article-title":"Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.","volume":"402","author":"Garvey","year":"2023","journal-title":"Lancet"},{"issue":"9","key":"zoi241598r37","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1001\/jamainternmed.2024.2525","article-title":"Semaglutide vs tirzepatide for weight loss in adults with overweight or obesity.","volume":"184","author":"Rodriguez","year":"2024","journal-title":"JAMA Intern Med"},{"issue":"4","key":"zoi241598r38","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1056\/NEJMoa2401943","article-title":"Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis.","volume":"391","author":"Loomba","year":"2024","journal-title":"N Engl J Med"},{"key":"zoi241598r39","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1324095","article-title":"Online searches for hepatocellular carcinoma drugs mirror prescription trends across specialties and changes in guideline recommendations.","volume":"14","author":"Berning","year":"2024","journal-title":"Front Oncol"},{"key":"zoi241598r1","unstructured":"Obesity and overweight. World Health Organization; 2023. Accessed November 17, 2023. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/obesity-and-overweight"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2829700\/berning_2025_oi_241598_1737568408.18035.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T12:40:22Z","timestamp":1738154422000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2829700"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,29]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1,2]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.57232","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,29]]}}}